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reached CZK885,044 (~EUR32,260), with the Cardiohelp device (Maquet, Germany) 
CZK788,432 (~EUR28,738). The cost utility analysis revealed 3,961,970 CZK/QALY 
(~144,413 EUR/QALY) with Cardiohelp, and 4,447,457 CZK/QALY (~162,109 EUR/
QALY) when using Levitronix Centrimag. However, if only patients with CPC 1 were 
included into the analysis, the cost-utility ratio decreased to 834,616 CZK/QALY 
(~30,422 EUR/QALY) and 908,253 CZK/QALY (~33,106 EUR/QALY) for Cardiohelp and 
Levitronix, respectively. ConClusions: Our data indicate that ECPR for refractory 
cardiac arrest might be cost effective despite the high costs per individual patient 
treated with this approach. Larger studies are, however, required to confirm these 
observations.
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objeCtives: Raised heart rate is a risk factor for cardiovascular events and 
death. Heart rate reduction could be an important role in management of chronic 
heart failure. Ivabradine is a new, pure and specific heart rate lower therapy. We 
assessed the cost effectiveness of Ivabradine in CHF with heart rate 75 bpm 
using the perspective of a middle-income country’s public health insurance sys-
tem. Methods: Model-based analysis closely mirrored the SHIFT trial was per-
formed. Micro-simulation method of CHF disease, mortality and hospitalization 
were used to compare Ivabradine plus standard care with standard care only. 
A two state Markov model has been employed to simulate the natural history of 
disease. Costs were estimated from national health insurance research database 
in Taiwan, a single-payer program that offers universal health care coverage. And 
another estimated costs using a medical center in Taiwan with clinical examina-
tion value were performed to validate the accuracy of costs. Incremental cost per 
quality adjusted life year (QALY) gained is used to express the value of Ivabradine 
over a lifetime horizon and 29 months of trial period. Results: The incremen-
tal cost per additional QALY for Ivabradine plus standard care versus standard 
care has been estimated as £14,832 for trial period and £7,634 for lifetime. 
Ivabradine is cost-effective according to NICE threshold. And the result was 
robust in sensitivity analysis. ConClusions: In a middle-income country like 
Taiwan, the use of Ivabradine to treat the eligible CHF patients is likely to be cost 
effectiveness.
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objeCtives: To conduct an economic analysis of the risk assessment of venous 
thromboembolism (VTE) from the perspective of the Spanish National Health 
System with Thrombo inCode versus conventional/standard method used to date 
(Factor V Leiden and Prothrombin G20210A). Methods: An economic model 
was created from the National Health System perspective using a decision tree 
in patients aged 45 with a life expectancy of 81 years. The predictive capacity of 
VTE based on the identification of thrombophilia with Thrombo inCode and of the 
standard method was obtained from two case-control studies (S. PAU and MARTHA) 
conducted on two different populations (1,451 patients in all). Although this is not 
always the case, in this analysis the least favourable situation was assumed for 
Thrombo inCode, with patients identified as suffering from thrombophilia being 
subject to preventive treatment of VTE with warfarin, leading to a reduction in 
the number of VTE events and an increased risk of severe bleeding. The health 
states utilities (quality-adjusted life years, QALY) and costs were obtained from 
the literature and Spanish sources. Results: Based on a price of € 180 for Thrombo 
inCode, this would be the dominant option (more effective and with lower costs than 
the standard method) in both populations. The Monte Carlo probabilistic analyses 
indicate that the dominance would occur in 100% of the simulations in both popu-
lations. The threshold price of Thrombo inCode needed to reach the incremental 
cost-effective ratio (ICER) generally accepted in Spain (€ 30,000 per QALY gained) 
would be between € 3,950 (MARTHA) and € 11,993 (S. PAU). ConClusions: Thrombo 
inCode is a dominant option in assessing the risk of VTE compared to the standard 
method currently used.
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objeCtives: Treatment of varicose veins (VV) has been shown to increase health 
related quality of life. However, the cost-effectiveness of such treatments has been 
uncertain. Indeed there is great regional variation across the UK in how, and if, VV 
are treated. This economic analysis formed part of the NICE clinical guideline on VV, 
with an objective to investigate whether such treatments should be recommended 
across the UK. Methods: An economic analysis was conducted to compare the 
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objeCtives: Non-invasive molecular imaging tests are currently being developed 
to improve individual stroke risk prediction in patients with a recent transient 
ischemic attack (TIA) or minor ischemic stroke. We estimated the minimum per-
formance (i.e., sensitivity and specificity) that a test must have in order to be more 
cost-effective than current clinical practice. Methods: The aim of imaging tests is 
to identify which patients should undergo surgery instead of receiving medicines. 
Decision modelling was used to estimate the minimum performance of a confirma-
tory test that is performed based on the result of an initial duplex ultrasonography. 
The comparators were patient management according to Dutch guidelines and three 
observed clinical practice strategies. Scenario analyses were performed in which the 
sensitivity and specificity were varied to estimate the minimum test performance 
needed to be cost-effective versus the comparators. Results: A perfect confirma-
tory test (100% sensitivity and specificity) with a cost of € 390 for a 60-year-old man 
is cost-effective versus all comparators. Assuming 100% sensitivity, a test must be at 
least 71% specific to be cost-effective versus the Dutch guidelines using a threshold 
of € 30,000/QALY. Similarly, assuming 100% specificity, a test must be at least 52% 
sensitive to be cost-effective. In addition, assuming 90% sensitivity, a test must have 
a specificity of at least 77% to be cost-effective. Moreover, the minimum values of 
sensitivity and specificity needed for a test to be cost-effective are dependent on the 
QALY threshold used. ConClusions: An imaging test that improves risk prediction 
and therefore treatment decisions for patients with a recent TIA or minor ischemic 
stroke has the potential to improve cost-effectiveness by reducing the risk of recur-
rent stroke. However, developers must consider if the minimum test performance 
required to be cost-effective can be achieved; other concerns of payers (e.g. budget 
impact) must also be considered.
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objeCtives: Guidelines suggest only 3-6 months of anticoagulant treatment in 
most venous thromboembolism (VTE) patients due to concerns that the bleeding 
risk with vitamin K antagonists (VKAs) outweighs the reduced risk of VTE recur-
rence in extended treatment. However, non-VKA novel oral anticoagulants (NOACs) 
have been studied recently for extended VTE treatment. Apixaban demonstrated 
superiority to placebo in VTE reduction without increasing risk of major bleeding in 
the AMPLIFY-EXT trial, justifying reassessment of the potential benefit of extending 
treatment. This analysis reports cost effectiveness of lifetime treatment with apixa-
ban versus rivaroxaban, dabigatran, and low-molecular-weight heparin (LMWH)/
KA from the perspective of the UK National Health Service (NHS). Methods: 
A Markov model was developed that includes the following health states: recurrent 
VTE, major bleed, clinically-relevant non-major bleed, chronic thromboembolic 
pulmonary hypertension, and death. Transition rates among health states were 
based upon AMPLIFY and AMPLIFY-EXT clinical trial data, network meta-analyses, 
discontinuation due to clinical events, and UK life tables. Costs were from UK NHS 
Healthcare Resource Group tables and utilities were from published literature. The 
primary outcome of interest was incremental cost per quality adjusted life year 
(QALY) gained. Results: Compared to other anticoagulants, lifetime treatment 
with apixaban was projected to result in fewer bleeds and fewer recurrent VTEs. 
The lower bleeding risk with apixaban led to fewer treatment discontinuations, 
longer time on treatment, and fewer recurrent VTEs. The reduced number of clini-
cal events led to increased QALYs at a nominal cost increase, due primarily to 
longer treatment duration with apixaban. Incremental costs per QALY gained 
were £2,781, £619, and £10,820 for apixaban versus dabigatran, rivaroxaban, and 
LMWH/VKA, respectively. Sensitivity analyses indicated that results were robust 
to a wide range of inputs. ConClusions: Apixaban for lifetime treatment of VTE 
can offer substantial clinical benefits and is a cost-effective alternative to other 
NOACs and LMWH/VKA.
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objeCtives: Extracorporeal life support (ECLS) has been recently introduced as a 
therapeutic option for refractory cardiac arrest (extracorporeal cardiopulmonary 
resuscitation - ECPR). Despite growing evidence demonstrating improved sur-
vival rate with ECPR in refractory cardiac arrest, a number of questions remains 
unanswered and data on cost-effectiveness of this approach are still insuffi-
cient. Methods: Retrospective cost-effectiveness analysis was performed from 
the provider’s perspective. Sixteen patients undergoing ECPR were included into 
the analysis (ECPR group) and the data were compared with 35 subjects with con-
ventional CPR for refractory cardiac arrest (non-ECPR group). Results: In the 
ECPR group seven out of sixteen patients were weaned from ECMO, four of them 
with good neurological outcomes (CPC 1); three patients survived one year with 
CPC 1, one patient survived one year with severe neurological dysfunction (CPC 
3) and one patient with persisting coma (CPC 4). In comparison, in the non-ECPR 
group all patients died within 24 hours. In the ECPR group, when using Levitronix 
Centrimag blood pump (Thoratec, USA), the average annual costs per patient 
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cost-effective over rivaroxaban. ConClusions: In patients treated for acute pul-
monary embolism, dabigatran is a cost-effective alternative compared with both 
warfarin and rivaroxaban.
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objeCtives: To evaluate cost-effectiveness of the novel oral anticoagulant apixa-
ban compared to warfarin and aspirin in patients with NVAF from the Russian 
Federation national health care system perspective. Methods: Cost-effectiveness 
analysis was based on a Markov model that allowed estimation of the incremen-
tal cost-effectiveness ratio (ICER) for apixaban compared to warfarin and aspirin 
over lifetime horizon in vitamin K antagonists (VKA) suitable and VKA unsuitable 
patients with NVAF, respectively. The model enclosed cardiovascular event rates 
derived from the randomized clinical trials: ARISTOTLE and AVERROES. The fol-
lowing cardiovascular events were considered: ischemic and hemorrhagic stroke, 
intracranial hemorrhage, systemic embolism, other major bleeds, clinically rele-
vant non-major bleeds, myocardial infarction and cardiovascular hospitalizations. 
Characteristics of the baseline patients’ cohort including quality of INR control 
corresponded to the local population. Direct medical costs were determined based 
on the rates of the compulsory national medical insurance system. The price of 
the antithrombotic drugs was taken as a weighted average tender price in 2013. 
Cost-effectiveness threshold was set at 1,4 million rubles per quality-adjusted 
life year (QALY) gained and corresponded to the three times GDP per capita in 
the Russian Federation in 2013. One-way sensitivity analyses were undertaken to 
examine the effects of model drivers. Results: In the base case analysis it was 
demonstrated that apixaban compared to warfarin and aspirin provided additional 
0.187 and 0.214 QALYs, respectively. With that estimated ICER for apixaban com-
pared to warfarin and aspirin was 603.92 and 473.02 thousands rubles per QALY 
gained, respectively. Sensitivity analysis indicated that results were robust over 
explored range of inputs. ConClusions: According to the results of the modeling 
study apixaban may be considered as a cost-effective alternative to warfarin in 
VKA suitable patients and as a cost-effective alternative to aspirin in VKA unsuit-
able patients for NVAF treatment from the Russian Federation national health care 
system perspective.
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objeCtives: This economic evaluation aimed to assess the cost-effectiveness of 
dabigatran compared with warfarin, in the treatment and secondary prevention 
of acute venous thromboembolism (VTE) comprising deep vein thrombosis (DVT) 
and pulmonary embolism (PE), in the UK health care setting, based on safety 
and efficacy data collected during pivotal phase III trials. Methods: A life-time 
Markov state-transition cohort model was developed around the two primary 
composite endpoints in the pivotal trials: recurrent VTE and VTE-related death 
(rVTE), and major or clinically relevant bleeding (MCRB). Intervention-specific 
probabilities of events within the composite endpoint rVTE (recurrent DVT; recur-
rent PE) and the composite endpoint MCRB (intracranial haemorrhage; other major 
bleeds; non-major bleeds) were sourced from the pivotal trials. Beyond the trials 
follow-up period, the probability of rVTE was sourced from the literature. Long-
term consequences of VTE were considered, namely chronic thromboembolic pul-
monary hypertension and post-thrombotic syndrome. The perspective on costs 
was that of the NHS and Public Social Services. Health outcomes were assessed 
in quality-adjusted life years (QALY). Utility values for health states and events 
were EQ-5D data collected within the clinical trials, and the published literature. 
Probabilistic sensitivity analyses (PSA) were undertaken. Results: In patients 
with index DVT, the estimated incremental cost-effectiveness ratio (ICER) of treat-
ment with dabigatran compared with warfarin was £614 per QALY gained; in 
patients with index PE, the ICER was £1,285/QALY; in the pooled DVT/PE group, the 
ICER was £862/QALY. In the treatment followed by secondary prevention analysis, 
ICER was £8,319/QALY. PSA suggested that the probability of dabigatran being 
cost-effective at a threshold of £30,000/QALY was 90%, 81% and 94% in acute 
treatment and 96% in secondary prevention respectively. ConClusions: In a 
UK setting, dabigatran appears to be a cost-effective option for treatment and 
secondary prevention of VTE in patients with acute DVT and acute PE compared 
with warfarin.
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objeCtives: The aim of the study was to compare the cost-utility of the two single-
pill triple combination antihypertensive therapies available in the Greek market 
for patients with moderate to severe hypertension; the valsartan (V) against the 
olmesartan (O) combination with amlodipine (A) and hydrochlorothiazide (H).  
Methods: A Markov model with eight health states was constructed. The short-
cost-effectiveness of surgery, endodermal ablation (ETA), ultrasound guided foam 
sclerotherapy (UGFS) and compression stockings (CS). The analysis was based on a 
Markov decision model, which was developed in consultation with members of the 
NICE guideline development group (GDG). The model had a five year time horizon, 
and took the perspective of the UK National Health Service. Clinical inputs were 
based on a network meta-analysis (NMA), informed by a systematic review of the 
clinical literature. Outcomes were expressed as costs and quality adjusted life years 
(QALYs). Results: All interventional treatments were found to be cost-effective 
compared to CS at a cost- effectiveness threshold of £20,000 per QALY gained. ETA 
was found to be the most cost-effective strategy overall, with an incremental cost-
effectiveness ratio of £3,161 per QALY gained compared to UGFS. Surgery and CS 
were dominated by ETA. ConClusions: Interventional treatment for VV is cost-
effective in the UK NHS. Specifically, based on current data, ETA is the most cost-
effective treatment in people for whom it is suitable. The results of this research 
were used to inform recommendations within the NICE guideline on VV. Funding: 
This work was undertaken by the National Clinical Guideline Centre, which received 
funding from the National Institute for Health and Clinical Excellence (NICE). The 
views expressed in this publication are those of the authors and not necessarily 
of the institute.
PCV95
thE Cost-EffECtiVEnEss of dabiGatran EtExilatE ComParEd With 
riVaroxaban in thE trEatmEnt of aCutE VEnous thromboEmbolism in 
thE uk
Jugrin A.V.1, Ustyugova A.V.2, Urbich M.3, Lamotte M.1, Sunderland T.J.4
1IMS Health HEOR, Vilvoorde, Belgium, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, 
Germany, 3Boehringer Ingelheim Ltd, Bracknell, UK, 4Boehringer Ingelheim, Berkshire, UK
objeCtives: Venous thromboembolism (VTE) including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) is a common cardiovascular disorder. Acute 
VTE has been traditionally managed with short course parenteral anticoagulation 
followed by 3-6 months of a vitamin-K antagonist. Novel oral anticoagulants do 
not require routine coagulation monitoring and dose adjustment, thus potentially 
providing an alternative treatment option. The cost-effectiveness of dabigatran vs. 
rivaroxaban over a 6 months treatment course in the UK health care setting was 
evaluated in this research. Methods: A life-time Markov model was developed, 
encompassing recurrent VTE events and VTE-related deaths, and the most com-
mon adverse events during anticoagulation therapy: major or clinically relevant 
bleeds (MCRB). The model was populated with data from pooled RE-COVER and 
RE-COVER II dabigatran trials and the 6 months treatment duration subgroup of 
the rivaroxaban EINSTEIN-DVT and EINSTEIN-PE trials. Long-term consequences 
of VTE were considered. Costs were analysed from the NHS and Public Social 
Services perspectives. Health outcomes were assessed in quality-adjusted life 
years (QALY). Utility values for modelled health states were EQ-5D data from 
RE-COVER studies, and published data. Probabilistic sensitivity analyses (PSA) 
were undertaken. Results: In patients with index PE, 6 months treatment with 
dabigatran dominated treatment with rivaroxaban projecting less recurrent VTE 
and less MCRB at lower costs. Dabigatran was likely to remain cost-effective in 70% 
of cases at a threshold used in the UK of £30,000/QALY gained. Dabigatran contin-
ued to dominate treatment with rivaroxaban in patients with index DVT, project-
ing less non-fatal PE, less intra-cranial haemorrhages and less clinically relevant 
bleeds, but more recurrent DVT, with 68% likelihood of remaining cost-effective. 
In the pooled DVT/PE group, dabigatran dominated treatment with rivaroxaban 
and was 62% likely to remain cost-effective. ConClusions: Dabigatran is less 
costly and more effective than rivaroxaban when administered for 6 months after 
index PE, index DVT or both.
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objeCtives: This economic evaluation aimed to assess the cost-effectiveness 
of dabigatran etexilate for six months of treatment for acute pulmonary embo-
lism (PE) compared with warfarin and rivaroxaban in the UK health care set-
ting. Methods: A Markov state-transition cohort model was used to project the 
lifetime recurrence of PE and occurrence of deep vein thrombosis (DVT) in patients 
with initial acute PE. The incidence of recurrent venous thromboembolism (rVTE) 
was based on the relevant study endpoints of RE-COVER and RE-COVER II trials 
comparing dabigatran with warfarin, and the EINSTEIN-PE study for rivaroxaban. 
Intervention-specific probabilities of events within the composite efficacy end-
point and within the composite safety endpoint of major or clinically relevant 
bleeding (MCRB) were sourced from the very same randomised trials. Beyond 
the data from clinical studies, the probability of rVTE was sourced from the 
published literature. Long-term consequences of VTE were considered, namely 
chronic thromboembolic-induced pulmonary hypertension and post-thrombotic 
syndrome. The perspective on costs was that of the NHS and Public Social Services. 
Health outcomes were assessed in quality-adjusted life years (QALY). Utility val-
ues relevant to events and health staes were EQ-5D data from RE-COVER studies, 
and published literature. Probabilistic sensitivity analyses (PSA) were under-
taken. Results: Compared with warfarin, dabigatran projected similar number 
of rVTE, but was associated with less MCRB. The expected lifetime incremental 
cost-effectiveness ratios (ICERs) were £2,004/life years (LYs) and £1,285/QALYs. PSA 
showed 84% likelihood for dabigatran to remain cost-effective given a willingness-
to-pay of £30,000/QALY. When compared with rivaroxaban, treatment with dabi-
gatran was projected dominant,. Dabigatran projected less rVTE, less intracranial 
haemorrhages and clinical relevant non-major bleeds, but was associated with a 
higher risk of major bleeds. PSA showed 66% likelihood for dabigatran to remain 
